Symbols / SCNI $0.72 +2.86%
SCNI Chart
About
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.30M |
| Enterprise Value | 4.25B | Income | 347.00K | Sales | 1.15M |
| Book/sh | 1.47 | Cash/sh | 989000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 31 | IPO | — |
| P/E | 0.18 | Forward P/E | — | PEG | — |
| P/S | 2.00 | P/B | 0.49 | P/C | — |
| EV/EBITDA | -629.60 | EV/Sales | 3702.38 | Quick Ratio | 0.53 |
| Current Ratio | 0.71 | Debt/Eq | 29.98 | LT Debt/Eq | — |
| EPS (ttm) | 4.00 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | 36.10% | Earnings | 2024-05-15 16:00 | ROA | -39.55% |
| ROE | 17.92% | ROIC | — | Gross Margin | -146.99% |
| Oper. Margin | -4.87% | Profit Margin | 4.48% | Shs Outstand | 3.19M |
| Shs Float | 5.35B | Short Float | 1.34% | Short Ratio | 1.57 |
| Short Interest | — | 52W High | 6.18 | 52W Low | 0.61 |
| Beta | 1.90 | Avg Volume | 50.39K | Volume | 5.20K |
| Target Price | — | Recom | None | Prev Close | $0.70 |
| Price | $0.72 | Change | 2.86% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.71
Latest analyst target
3. DCF / Fair value
$-19.13
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.71
Low
—
High
—
Mean
—
- Scinai stock falls under Nasdaq’s $1 rule, 180 days to fix - Stock Titan Mon, 16 Mar 2026 20
- Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm - PR Newswire ue, 17 Feb 2026 08
- €12M bet on severe skin disease drug: Scinai pushes PC111 to human trials - Stock Titan Mon, 02 Mar 2026 08
- symbol__ Stock Quote Price and Forecast - CNN Wed, 27 Mar 2024 07
- Earnings Miss: What is the next catalyst for SCNI - 2026 Short Interest & Community Verified Swing Trade Signals - baoquankhu1.vn ue, 17 Mar 2026 07
- Scinai Wins Expanded Israel Innovation Authority Backing for Robotic Aseptic Platform - TipRanks Wed, 25 Feb 2026 08
- Israel backs robot-run sterile drug line with NIS 5M Scinai grant - Stock Titan Wed, 25 Feb 2026 08
- Scinai Immunotherapeutics Buys Recipharm Israel Unit, Seals Strategic CDMO Pact - TipRanks ue, 17 Feb 2026 08
- PLUG Stock Alert: Plug Power Gets Approval for HyVia Acquisition - InvestorPlace Mon, 15 Jul 2024 07
- Major Breakthrough: Scinai Clears Critical Hurdle in €12M Rare Disease Drug Acquisition Deal - Stock Titan hu, 05 Jun 2025 07
- Why Is Kaival Brands Innovations (KAVL) Stock Down 33% Today? - InvestorPlace Mon, 17 Jun 2024 07
- Why Is AMC Networks (AMCX) Stock Down 11% Today? - InvestorPlace Mon, 17 Jun 2024 07
- SCNI - Scinai Immunotherapeutics Ltd. Latest Stock News & Market Updates - Stock Titan Mon, 11 Sep 2023 11
- Scinai Immunotherapeutics receives Nasdaq notification regarding minimum bid price - marketscreener.com Mon, 16 Mar 2026 21
- Gift chain with Stamford, Norwalk stores declares bankruptcy - Stamford Advocate ue, 14 Jul 2020 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 3.40M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.23 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -6.90M | -5.28M | -7.47M | -9.90M |
| TotalUnusualItems | 14.77M | 3.09M | 2.23M | -487.00K |
| TotalUnusualItemsExcludingGoodwill | 14.77M | 3.09M | 2.23M | -487.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | 4.80M | -6.50M | -5.80M | -8.21M |
| ReconciledDepreciation | 1.65M | 514.00K | 562.00K | 471.00K |
| ReconciledCostOfRevenue | 1.24M | 0.00 | 0.00 | |
| EBITDA | 7.87M | -2.19M | -5.23M | -10.39M |
| EBIT | 6.22M | -2.70M | -5.80M | -10.86M |
| NetInterestIncome | -1.33M | 115.00K | 3.03M | 3.14M |
| InterestExpense | 1.42M | 3.80M | 0.00 | 3.49M |
| InterestIncome | 100.00K | 3.92M | 3.05M | 3.15M |
| NormalizedIncome | -6.57M | -9.59M | -8.03M | -7.72M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 4.80M | -6.50M | -5.80M | -8.21M |
| TotalExpenses | 9.30M | 9.71M | 11.06M | 10.86M |
| RentExpenseSupplemental | 101.05K | |||
| TotalOperatingIncomeAsReported | -8.64M | -9.71M | -11.06M | -10.86M |
| DilutedAverageShares | 806.37K | 390.66K | 188.52K | 141.14K |
| BasicAverageShares | 806.37K | 390.66K | 188.52K | 141.14K |
| DilutedEPS | 0.00 | -16.00 | -40.00 | -80.00 |
| BasicEPS | 0.00 | -16.00 | -40.00 | -80.00 |
| DilutedNIAvailtoComStockholders | 0.00 | -6.50M | -5.80M | -8.21M |
| NetIncomeCommonStockholders | 0.00 | -6.50M | -5.80M | -8.21M |
| PreferredStockDividends | 4.80M | |||
| NetIncome | 4.80M | -6.50M | -5.80M | -8.21M |
| NetIncomeIncludingNoncontrollingInterests | 4.80M | -6.50M | -5.80M | -8.21M |
| NetIncomeContinuousOperations | 4.80M | -6.50M | -5.80M | -8.21M |
| PretaxIncome | 4.80M | -6.50M | -5.80M | -8.21M |
| OtherIncomeExpense | 14.77M | 3.09M | 2.23M | -487.00K |
| SpecialIncomeCharges | 14.76M | 0.00 | 0.00 | |
| OtherSpecialCharges | -14.76M | |||
| GainOnSaleOfSecurity | 7.00K | 3.09M | 2.23M | -487.00K |
| NetNonOperatingInterestIncomeExpense | -1.33M | 115.00K | 3.03M | 3.14M |
| TotalOtherFinanceCost | 10.00K | 8.00K | 21.00K | 9.00K |
| InterestExpenseNonOperating | 1.42M | 3.80M | 0.00 | 3.49M |
| InterestIncomeNonOperating | 100.00K | 3.92M | 3.05M | 3.15M |
| OperatingIncome | -8.64M | -9.71M | -11.06M | -10.86M |
| OperatingExpense | 8.06M | 9.71M | 11.06M | 10.86M |
| OtherOperatingExpenses | -9.00K | -12.00K | ||
| DepreciationAmortizationDepletionIncomeStatement | 176.68K | |||
| DepreciationAndAmortizationInIncomeStatement | 176.68K | |||
| DepreciationIncomeStatement | 176.68K | |||
| ResearchAndDevelopment | 5.53M | 5.21M | 5.76M | 3.25M |
| SellingGeneralAndAdministration | 2.53M | 4.50M | 5.30M | 7.62M |
| GeneralAndAdministrativeExpense | 7.72M | |||
| OtherGandA | 2.71M | |||
| RentAndLandingFees | 101.05K | |||
| SalariesAndWages | 4.90M | |||
| GrossProfit | -580.00K | 0.00 | 0.00 | |
| CostOfRevenue | 1.24M | 0.00 | 0.00 | |
| TotalRevenue | 658.00K | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 658.00K | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.41B | 1.86B | 989.29M | 739.05M |
| ShareIssued | 3.41B | 1.86B | 989.29M | 739.05M |
| NetDebt | 14.50M | 6.01M | 9.79M | |
| TotalDebt | 2.09M | 20.56M | 21.54M | 28.98M |
| TangibleBookValue | 4.35M | -4.57M | -1.76M | 982.00K |
| InvestedCapital | 4.61M | 14.80M | 18.32M | 28.15M |
| WorkingCapital | 585.00K | 3.67M | 12.03M | 15.40M |
| NetTangibleAssets | 9.98M | -4.57M | -1.76M | 982.00K |
| CapitalLeaseObligations | 1.83M | 1.19M | 1.46M | 1.82M |
| CommonStockEquity | 4.35M | -4.57M | -1.76M | 982.00K |
| PreferredStockEquity | 5.63M | |||
| TotalCapitalization | 10.24M | 14.80M | 18.32M | 28.15M |
| TotalEquityGrossMinorityInterest | 9.98M | -4.57M | -1.76M | 982.00K |
| StockholdersEquity | 9.98M | -4.57M | -1.76M | 982.00K |
| GainsLossesNotAffectingRetainedEarnings | -1.74M | -1.74M | -2.01M | -2.06M |
| OtherEquityAdjustments | -1.74M | -1.74M | -2.01M | -2.06M |
| RetainedEarnings | -117.54M | -122.33M | -115.83M | -110.04M |
| AdditionalPaidInCapital | 123.63M | 119.51M | 116.08M | 113.08M |
| CapitalStock | 5.63M | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 5.63M | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 3.47M | 22.04M | 28.83M | 31.05M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.67M | 20.26M | 26.49M | 28.61M |
| DerivativeProductLiabilities | 3.00K | 96.00K | 5.33M | 0.00 |
| EmployeeBenefits | 95.00K | |||
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 95.00K | |||
| TradeandOtherPayablesNonCurrent | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 1.66M | 20.16M | 21.16M | 28.61M |
| LongTermCapitalLeaseObligation | 1.40M | 797.00K | 1.08M | 1.45M |
| LongTermDebt | 260.00K | 19.37M | 20.08M | 27.16M |
| CurrentLiabilities | 1.81M | 1.78M | 2.34M | 2.44M |
| CurrentDeferredLiabilities | 225.00K | 0.00 | ||
| CurrentDeferredRevenue | 225.00K | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 424.00K | 396.00K | 382.00K | 375.00K |
| CurrentCapitalLeaseObligation | 424.00K | 396.00K | 382.00K | 375.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 484.00K | 709.00K | ||
| PayablesAndAccruedExpenses | 1.16M | 1.38M | 1.96M | 2.07M |
| CurrentAccruedExpenses | 781.00K | 849.00K | 1.24M | 1.07M |
| Payables | 376.00K | 535.00K | 716.00K | 999.00K |
| AccountsPayable | 376.00K | 535.00K | 716.00K | 999.00K |
| TotalAssets | 13.45M | 17.47M | 27.07M | 32.04M |
| TotalNonCurrentAssets | 11.06M | 12.03M | 12.70M | 14.19M |
| OtherNonCurrentAssets | 444.00K | |||
| NetPPE | 11.06M | 12.03M | 12.70M | 14.19M |
| AccumulatedDepreciation | -4.46M | -2.81M | -2.42M | -2.13M |
| GrossPPE | 15.51M | 14.83M | 15.12M | 16.32M |
| Leases | 3.72M | 3.72M | 3.92M | 4.43M |
| ConstructionInProgress | 0.00 | 7.45M | 7.83M | 8.86M |
| OtherProperties | 4.02M | 3.34M | 3.04M | 2.69M |
| MachineryFurnitureEquipment | 7.77M | 321.00K | 332.00K | 339.00K |
| BuildingsAndImprovements | 7.83M | |||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.39M | 5.45M | 14.37M | 17.84M |
| RestrictedCash | 131.00K | 140.00K | 140.00K | 143.00K |
| PrepaidAssets | 79.00K | 71.00K | 45.00K | 228.00K |
| Receivables | 217.00K | 366.00K | 110.00K | 98.00K |
| OtherReceivables | 134.00K | 366.00K | 110.00K | 98.00K |
| AccountsReceivable | 83.00K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 1.96M | 4.87M | 14.07M | 17.37M |
| CashAndCashEquivalents | 1.96M | 4.87M | 14.07M | 17.37M |
| CashFinancial | 54.04M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -6.35M | -10.02M | -8.10M | -7.57M |
| RepaymentOfDebt | -392.62K | |||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 2.00M | 139.00K | 932.00K | 21.43M |
| CapitalExpenditure | -12.00K | -637.00K | -836.00K | -139.00K |
| InterestPaidSupplementalData | 143.00K | 833.00K | 916.00K | 0.00 |
| EndCashPosition | 2.10M | 5.01M | 14.21M | 17.52M |
| BeginningCashPosition | 5.01M | 14.21M | 17.52M | 3.08M |
| EffectOfExchangeRateChanges | -9.00K | -272.00K | -1.98M | 575.00K |
| ChangesInCash | -2.91M | -8.93M | -1.32M | 13.87M |
| FinancingCashFlow | 3.44M | 1.09M | 6.78M | 21.43M |
| CashFlowFromContinuingFinancingActivities | 3.44M | 1.09M | 6.78M | 21.43M |
| ProceedsFromStockOptionExercised | 1.44M | 947.00K | 5.84M | 0.00 |
| NetCommonStockIssuance | 2.00M | 139.00K | 932.00K | 21.43M |
| CommonStockIssuance | 2.00M | 139.00K | 932.00K | 21.43M |
| NetIssuancePaymentsOfDebt | -392.62K | |||
| NetLongTermDebtIssuance | -392.62K | |||
| LongTermDebtPayments | -392.62K | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -12.00K | -637.00K | -836.00K | -139.00K |
| CashFlowFromContinuingInvestingActivities | -12.00K | -637.00K | -836.00K | -139.00K |
| NetOtherInvestingChanges | 9.33K | |||
| NetPPEPurchaseAndSale | -12.00K | -637.00K | -836.00K | -139.00K |
| SaleOfPPE | 12.87K | |||
| PurchaseOfPPE | -12.00K | -637.00K | -836.00K | -139.00K |
| OperatingCashFlow | -6.33M | -9.38M | -7.26M | -7.43M |
| CashFlowFromContinuingOperatingActivities | -6.33M | -9.38M | -7.26M | -7.43M |
| InterestReceivedCFO | 0.00 | |||
| InterestPaidCFO | -10.62K | |||
| ChangeInWorkingCapital | 112.00K | -796.00K | 271.00K | 704.00K |
| ChangeInOtherCurrentLiabilities | -314.00K | -58.00K | -156.00K | -150.00K |
| ChangeInOtherCurrentAssets | 284.00K | 43.00K | 153.00K | 148.00K |
| ChangeInPayablesAndAccruedExpense | 1.00K | -491.00K | 134.00K | 647.00K |
| ChangeInPayable | 1.00K | -491.00K | 134.00K | 647.00K |
| ChangeInAccountPayable | -156.00K | -150.00K | -175.00K | 3.00K |
| ChangeInReceivables | 141.00K | -290.00K | 140.00K | 59.00K |
| ChangesInAccountReceivables | -83.00K | |||
| OtherNonCashItems | -13.48M | 401.00K | -3.90M | -3.15M |
| StockBasedCompensation | 682.00K | 1.14M | 1.60M | 2.76M |
| DepreciationAmortizationDepletion | 1.65M | 514.00K | 562.00K | 471.00K |
| DepreciationAndAmortization | 1.65M | 514.00K | 562.00K | 471.00K |
| Depreciation | 1.65M | 514.00K | 562.00K | 471.00K |
| OperatingGainsLosses | -93.00K | -4.14M | ||
| PensionAndEmployeeBenefitExpense | 0.00 | |||
| GainLossOnInvestmentSecurities | -93.00K | -4.14M | ||
| NetIncomeFromContinuingOperations | 4.80M | -6.50M | -5.80M | -8.21M |
Public Trades for SCNI
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|